Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2018
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Primary biliary cirrhosis
- Focus Therapeutic Use
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.